• HARINE AG Department of Pharmacology, SRM College of Pharmacy, SRM Institute of Science and Technology, Kattankulathur, Chennai, Tamil Nadu, India.
  • SUMITRA M Department of Pharmacology, SRM College of Pharmacy, SRM Institute of Science and Technology, Kattankulathur, Chennai, Tamil Nadu,
  • CHITRA V Department of Pharmacology, SRM College of Pharmacy, SRM Institute of Science and Technology, Kattankulathur, Chennai, Tamil Nadu, India.


Prostatitis is an inflammatory disease, when the prostate is vulnerable to infectious stimuli like urinary pathogens, are changes in the lifestyle leads to inflammation in the prostate gland. It is a pathological state where the swelling of prostate occur to most of the men and mainly elderly. Recently, prostatitis is a dangerous threat for men almost 50% total men population. The review comprises complete information regarding prostatitis and its related complications. The compilation of the data is about the disease from classification of prostatitis, causative agents, symptoms, treatment, mitigation, natural and alternative therapy to improve the quality of life. Awareness of this disease is not known to the majority of the population when it is left untreated identification and treatment at the right time help in increase in recovering from the pathological condition of the victim to overcome.

Keywords: Urinary pathogens, Prostatitis, Causative agents, Alternative therapy.

Author Biography

HARINE AG, Department of Pharmacology, SRM College of Pharmacy, SRM Institute of Science and Technology, Kattankulathur, Chennai, Tamil Nadu, India.



1. Available from:
2. Krieger JN, Nyberg L Jr., Nickel JC. NIH consensus definition and classification of prostatitis. JAMA 1999;282:236-7.
3. Schaeffer AJ. Clinical practice. Chronic prostatitis and the chronic pelvic pain syndrome. N Engl J Med 2006;355:1690-8.
4. Skerk V, Krhen I, Schonwald S, Cajic V, Markovinovic L, Roglic S, et al. The role of unusual pathogens in prostatitis syndrome. Int J Antimicrob Agents 2004;24 Suppl 1:S53-6.
5. Morgia G, Mucciardi G, Galì A, Madonia M, Marchese F, Di Benedetto A, et al. Treatment of chronic prostatitis/chronic pelvic pain syndrome category IIIA with Serenoa repens plus selenium and lycopene (Profluss) versus S. repens alone: An Italian randomized multicenter-controlled study. Urol Int 2010;84:400-6.
6. Krieger JN, Riley DE. Prostatitis: What is the role of infection. Int J Antimicrob Agents 2002;19:475-9.
7. Murphy AB, Macejko A, Taylor A, Nadler RB. Chronic prostatitis: Management strategies. Drugs 2009;69:71-84.
8. Leskinen MJ, Rantakokko-Jalava K, Manninen R, Leppilahti M, Marttila T, Kylmälä T, et al. Negative bacterial polymerase chain reaction (PCR) findings in prostate tissue from patients with symptoms of chronic pelvic pain syndrome (CPPS) and localized prostate cancer. Prostate 2003;55:105-10.
9. Lee JC, Muller CH, Rothman I, Agnew KJ, Eschenbach D, Ciol MA, et al. Prostate biopsy culture findings of men with chronic pelvic pain syndrome do not differ from those of healthy controls. J Urol 2003;169:584-7.
10. Anderson RU, Orenberg EK, Morey A, Chavez N, Chan CA. Stress induced hypothalamus-pituitary-adrenal axis responses and disturbances in psychological profiles in men with chronic prostatitis/ chronic pelvic pain syndrome. J Urol 2009;182:2319-24.
11. Nickel JC, Roehrborn CG, O’leary MP, Bostwick DG, Somerville MC, Rittmaster RS, et al. Examination of the relationship between symptoms of prostatitis and histological inflammation: Baseline data from the REDUCE chemoprevention trial. J Urol 2007;178:896-900.
12. Rodríguez MA, Afari N, Buchwald DS; National Institute of Diabetes and Digestive and Kidney Diseases Working Group on Urological Chronic Pelvic Pain. Evidence for overlap between urological and nonurological unexplained clinical conditions. J Urol 2009;182:2123-31.
13. Trinchieri A, Magri V, Cariani L, Bonamore R, Restelli A, Garlaschi MC, et al. Prevalence of sexual dysfunction in men with chronic prostatitis/ chronic pelvic pain syndrome. Arch Ital Urol Androl 2007;79:67-70.
14. Krieger JN, Ross SO, Penson DF, Riley DE. Symptoms and inflammation in chronic prostatitis/chronic pelvic pain syndrome. Urology 2002;60:959-63.
15. Nickel JC, Weidner W. Chronic prostatitis: Current concepts and antimicrobial therapy. Infect Urol 2000;13:s22-8.
16. Gandaglia G, Zaffuto E, Fossati N, Cucchiara V, Mirone V, Montorsi F, et al. The role of prostatic inflammation in the development and progression of benign and malignant diseases. Curr Opin Urol 2017;27:99-106.
17. Chen CS, Chang PJ, Lin WY, Huang YC, Ho DR. Evidences of the inflammasome pathway in chronic prostatitis and chronic pelvic pain syndrome in an animal model. Prostate 2013;73:391-7.
18. Kummer JA, Broekhuizen R, Everett H, Agostini L, Kuijk L, Martinon F, et al. Inflammasome components NALP 1 and 3 show distinct but separate expression profiles in human tissues suggesting a site-specific role in the inflammatory response. J Histochem Cytochem 2007;55:443-52.
19. Ponomareva L, Liu H, Duan X, Dickerson E, Shen H, Panchanathan R, et al. AIM2, an IFN-inducible cytosolic DNA sensor, in the development of benign prostate hyperplasia and prostate cancer. Mol Cancer Res 2013;11:1193-202.
20. Roehrborn CG. BPH progression: Concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE. BJU Int 2008;101 Suppl 3:17-21.
21. Ficarra V, Rossanese M, Zazzara M, Giannarini G, Abbinante M, Bartoletti R, et al. The role of inflammation in lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) and its potential impact on medical therapy. Curr Urol Rep 2014;15:463.
22. Gandaglia G, Briganti A, Gontero P, Mondaini N, Novara G, Salonia A, et al. The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH). BJU Int 2013;112:432-41.
23. Elkahwaji JE. The role of inflammatory mediators in the development of prostatic hyperplasia and prostate cancer. Res Rep Urol 2012;5:1-10.
24. Nguyen DP, Li J, Yadav SS, Tewari AK. Recent insights into NF-?B signalling pathways and the link between inflammation and prostate cancer. BJU Int 2014;114:168-76.
25. Bauernfeind FG, Horvath G, Stutz A, Alnemri ES, MacDonald K, Speert D, et al. Cutting edge: NF-kappaB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression. J Immunol 2009;183:787-91.
26. Moreira DM, Nickel JC, Gerber L, Muller RL, Andriole GL, Castro- Santamaria R, et al. Baseline prostate inflammation is associated with a reduced risk of prostate cancer in men undergoing repeat prostate biopsy: Results from the REDUCE study. Cancer 2014;120:190-6.
27. Yli-Hemminki TH, Laurila M, Auvinen A, Määttänen L, Huhtala H, Tammela TL, et al. Histological inflammation and risk of subsequent prostate cancer among men with initially elevated serum prostate-specific antigen (PSA) concentration in the Finnish prostate cancer screening trial. BJU Int 2013;112:735-41.
28. Powell IJ, Dyson G, Land S, Ruterbusch J, Bock CH, Lenk S, et al. Genes associated with prostate cancer are differentially expressed in African American and European American men. Cancer Epidemiol Biomarkers Prev 2013;22:891-7.
29. Wallace TA, Prueitt RL, Yi M, Howe TM, Gillespie JW, Yfantis HG, et al. Tumor immunobiological differences in prostate cancer between African-American and European-American men. Cancer Res 2008;68:927-36.
30. Vide?nik Zorman J, Mati?i? M, Jeverica S, Smrkolj T. Diagnosis and treatment of bacterial prostatitis. Acta Dermatovenerol Alp Pannonica Adriat 2015;24:25-9.
31. Kirby RS, Lowe D, Bultitude MI, Shuttleworth KE. Intra-prostatic urinary reflux: An aetiological factor in abacterial prostatitis. Br J Urol 1982;54:729-31.
32. Nyberg LM, Krieger JN, Nickel JC. Textbook of Prostatitis. Oxford, United Kingdom: National Institutes of Health Classification of Chronic Prostatitis; 1999. p. 27-9.
33. Weiss J, Wein A, Jacobs J, Hanno P. Use of nitrofurantoin macrocrystals after transurethral prostatectomy. J Urol 1983;130:479-80.
34. De Nunzio C, Aronson W, Freedland SJ, Giovannucci E, Parsons JK. The correlation between metabolic syndrome and prostatic diseases. Eur Urol 2012;61:560-70.
35. Freeman MR, Solomon KR. Cholesterol and benign prostate disease. Differentiation 2011;82:244-52.
36. Vignozzi L, Gacci M, Maggi M. Lower urinary tract symptoms, benign prostatic hyperplasia and metabolic syndrome. Nat Rev Urol 2016;13:108-19.
37. Moreira DM, Nickel JC, Gerber L, Muller RL, Andriole GL, Castro- Santamaria R, et al. Smoking is associated with acute and chronic prostatic inflammation: Results from the REDUCE study. Cancer Prev Res (Phila) 2015;8:312-7.
38. Shankar E, Bhaskaran N, MacLennan GT, Liu G, Daneshgari F, Gupta S, et al. Inflammatory signaling involved in high-fat diet induced prostate diseases. J Urol Res 2015;2:1018.
39. Ghaemi-Oskouie F, Shi Y. The role of uric acid as an endogenous danger signal in immunity and inflammation. Curr Rheumatol Rep 2011;13:160-6.
40. Lamkanfi M, Dixit VM. Mechanisms and functions of inflammasomes. Cell 2014;157:1013-22.
41. Sutterwala FS, Haasken S, Cassel SL. Mechanism of NLRP3 inflammasome activation. Ann N Y Acad Sci 2014;1319:82-95.
42. Wen H, Miao EA, Ting JP. Mechanisms of NOD-like receptor-associated inflammasome activation. Immunity 2013;39:432-41.
43. He WT, Wan H, Hu L, Chen P, Wang X, Huang Z, et al. Gasdermin D is an executor of pyroptosis and required for interleukin-1? secretion. Cell Res 2015;25:1285-98.
44. Kayagaki N, Stowe IB, Lee BL, O’Rourke K, Anderson K, Warming S, et al. Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling. Nature 2015;526:666-71.
45. Shi J, Zhao Y, Wang Y, Gao W, Ding J, Li P, et al. Inflammatory caspases are innate immune receptors for intracellular LPS. Nature 2014;514:187-92.
46. Shi Y, Evans JE, Rock KL. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 2003;425:516.
47. Kayagaki N, Wong MT, Stowe IB, Ramani SR, Gonzalez LC, Akashi-Takamura S, et al. Noncanonical inflammasome activation by intracellular LPS independent of TLR4. Science 2013;25:1240-8.
48. Guo H, Callaway JB, Ting JP. Inflammasomes: Mechanism of action, role in disease, and therapeutics. Nat Med 2015;21:677-87.
49. Jiménez Fernández D, Lamkanfi M. Inflammatory caspases: Key regulators of inflammation and cell death. Biol Chem 2015;396:193-203.
50. Roberts JS, Yilma Z. Dangerous liaisons: Caspase-11 and reactive oxygen species crosstalk in pathogene limination. Int J Mol Sci 2015;16:23337-54.
51. Lotti F, Maggi M. Interleukin 8 and the male genital tract. J Reprod Immunol 2013;100:54-65.
52. Boehm BJ, Colopy SA, Jerde TJ, Loftus CJ, Bushman W. Acute bacterial inflammation of the mouse prostate. Prostate 2012;72:307-17.
53. Steiner GE, Stix U, Handisurya A, Willheim M, Haitel A, Reithmayr F, et al. Cytokine expression pattern in benign prostatic hyperplasia infiltrating T cells and impact of lymphocytic infiltration on cytokine mRNA profile in prostatic tissue. Lab Invest 2003;83:1131-46.
54. Theyer G, Kramer G, Assmann I, Sherwood E, Preinfalk W, Marberger M, et al. Phenotypic characterization of infiltrating leukocytes in benign prostatic hyperplasia. Lab Invest 1992;66:96-107.
55. Haverkamp JM, Charbonneau B, Crist SA, Meyerholz DK, Cohen MB, Snyder PW, et al. An inducible model of abacterial prostatitis induces antigen specific inflammatory and proliferative changes in the murine prostate. Prostate 2011;71:1139-50.
56. Kramer G, Mitteregger D, Marberger M. Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? Eur Urol 2007;51:1202-16.
57. Penna G, Fibbi B, Amuchastegui S, Cossetti C, Aquilano F, Laverny G, et al. Human benign prostatic hyperplasia stromal cells as inducers and targets of chronic immuno-mediated inflammation. J Immunol 2009;182:4056-64.
58. Nickel JC. Prostatitis. Can Urol Assoc J 2011;5:306-15.
59. Horcajada JP, Vilana R, Moreno-martínez A, Alvarez-vijande R, Bru C, Bargalló X, et al. Transrectal prostatic ultrasonography in acute bacterial prostatitis: Findings and clinical implications. Scand J Infect Dis 2003;35:114-20.
60. Dickson G. Prostatitis: Diagnosis and treatment. Aust Fam Physician 2013;42:216.
61. Xia D, Wang P, Chen J, Wang S, Jiang H. Fluoxetine ameliorates symptoms of refractory chronic prostatitis/chronic pelvic pain syndrome. Chin Med J (Engl) 2011;124:2158-61.
62. Tirlapur SA, Vlismas A, Ball E, Khan KS. Nerve stimulation for chronic pelvic pain and bladder pain syndrome: A systematic review. Acta Obstet Gynecol Scand 2013;92:881-7.
63. Osborn DE, George NJ, Rao PN, Barnard RJ, Reading C, Marklow C, et al. Prostatodynia – physiological characteristics and rational management with muscle relaxants. Br J Urol 1981;53:621-3.
64. Buck AC, Rees RW, Ebeling L. Treatment of chronic prostatitis and prostatodynia with pollen extract. Br J Urol 1989;64:496-9.
65. Shoskes DA, Zeitlin SI, Shahed A, Rajfer J. Quercetin in men with category III chronic prostatitis: A preliminary prospective, double-blind, placebo-controlled trial. Urology 1999;54:960-3.
66. Capodice JL, Jin Z, Bemis DL, Samadi D, Stone BA, Kapan S, et al. A pilot study on acupuncture for lower urinary tract symptoms related to chronic prostatitis/chronic pelvic pain. Chin Med 2007;2:1.
67. Nickel JC. Prostatitis and related conditions, orchitis, and epididymitis. In: Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA, editors. Campbell-Walsh Urology. 10th ed. Philadelphia, PA: Saunders; 2012. p. 327-56.
68. Huang YS, Yu QQ, Chen Y, Cheng MJ, Xie LP. Phenolic constituents from Alisma plantago-aquatica Linnaeus and their anti-chronic prostatitis activity. Chem Cent J 2017;11:120.
69. Elberry AA, Mufti ST, Al-Maghrabi JA, Abdel-Sattar EA, Ashour OM, Ghareib SA, et al. Anti-inflammatory and antiproliferative activities of date palm pollen (Phoenix dactylifera) on experimentally-induced atypical prostatic hyperplasia in rats. J Inflamm (Lond) 2011;8:40.
70. Asakawa K, Nandachi N, Satoh S, Honma M, Namikata S, Ishii M, et al. Effects of cernitin pollen-extract (Cernilton) on inflammatory cytokines in sex-hormone-induced nonbacterial prostatitis rats. Hinyokika Kiyo 2001;47:459-65.
71. Dumbre RK, Kamble MB, Patil VR. Inhibitory effects by Ayurvedic plants on prostate enlargement induced in rats. Pharmacognosy Res 2014;6:127-32.
72. Dvorkin L, Song KY. Herbs for benign prostatic hyperplasia. Ann Pharmacother 2002;36:1443-52.
73. Curtis Nickel J, Shoskes D, Roehrborn CG, Moyad M. Nutraceuticals in prostate disease: The urologist’s role. Rev Urol 2008;10:192-206.
74. Sohn DW, Han CH, Jung YS, Kim SI, Kim SW, Cho YH, et al. Anti-inflammatory and antimicrobial effects of garlic and synergistic effect between garlic and ciprofloxacin in a chronic bacterial prostatitis rat model. Int J Antimicrob Agents 2009;34:215-9.
75. Rani P, Singh K, Devi S, Arjuna A. Detection of prostate cancer: A Review. Asian J Pharm Clin Res 2018;11:974-2441.
76. Mansouri F. The role of the clinical and molecular assays in prostate cancer detection. Asian J Pharm Clin Res 2017;10:11-5.
267 Views | 430 Downloads
How to Cite
AG, H., S. M, and C. V. “CONSUMMATED REVIEW ON PROSTATITIS”. Asian Journal of Pharmaceutical and Clinical Research, Vol. 12, no. 3, Mar. 2019, pp. 1-7, doi:10.22159/ajpcr.2019.v12i3.29307.
Review Article(s)